Results from a post-hoc exploratory subgroup analysis from the NIAGARA Phase III trial showed AstraZeneca’s Imfinzi (durvalumab), administered perioperatively in combination with neoadjuvant chemotherapy, demonstrated improvements in event-free… read more.
New subgroup data from the Phase III ARANOTE trial show darolutamide plus androgen deprivation therapy (ADT) improved radiological progression-free survival (rPFS) in patients with high and low-volume metastatic… read more.
Medtronic announced that the Expand URO Investigational Device Exemption (IDE) clinical study, the largest such study for robotic-assisted urologic surgery ever conducted, met both primary safety and effectiveness… read more.
The menopause transition is often accompanied by a wide array of symptoms, some of which receive more attention than others. Bladder health and lower urinary tract issues are… read more.
Researchers from the University of Missouri School of Medicine have shed new light on how the uterus develops, leading to a better understanding of female reproductive health while providing clues… read more.
AstraZeneca’s Imfinzi (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by Imfinzi as adjuvant monotherapy after radical cystectomy (surgery to remove the bladder) has been approved… read more.
Women with ongoing urinary incontinence could avoid invasive bladder pressure tests, as new research shows that a range of non-invasive assessments work just as well in guiding treatment…. read more.
GSK plc announced that the FDA has approved Blujepa (gepotidacin) for the treatment of female adults (≥40 kg) and paediatric patients (≥12 years, ≥40 kg) with uncomplicated urinary… read more.
Pfizer Inc. announced positive results from the Phase III TALAPRO-2 study of Talzenna, an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with Xtandi (enzalutamide), an androgen receptor… read more.
Using a high-pressure water jet to operate on an enlarged prostate can better preserve the ability to ejaculate, compared with standard laser surgery, finds research. The technique has… read more.
Pfizer Inc. announced positive topline results from the progression-free survival (PFS) analysis of the Phase III BREAKWATER study of Braftovi (encorafenib) in combination with cetuximab (Erbitux) and mFOLFOX6… read more.
Researchers from the University of Colorado Anschutz Medical Campus studied a new method to deliver antibiotics, specifically gentamicin, directly into the bladder tissue to better treat UTIs. They did this… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
